These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 27029942)
21. Advance in herpes simplex viruses for cancer therapy. Liu S; Dai M; You L; Zhao Y Sci China Life Sci; 2013 Apr; 56(4):298-305. PubMed ID: 23564184 [TBL] [Abstract][Full Text] [Related]
22. Cellular Antisilencing Elements Support Transgene Expression from Herpes Simplex Virus Vectors in the Absence of Immediate Early Gene Expression. Han F; Miyagawa Y; Verlengia G; Ingusci S; Soukupova M; Simonato M; Glorioso JC; Cohen JB J Virol; 2018 Sep; 92(17):. PubMed ID: 29950408 [TBL] [Abstract][Full Text] [Related]
23. A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells. Leoni V; Gatta V; Casiraghi C; Nicosia A; Petrovic B; Campadelli-Fiume G J Virol; 2017 May; 91(10):. PubMed ID: 28250120 [TBL] [Abstract][Full Text] [Related]
24. Oncolytic herpes simplex virus type 1 and host immune responses. Fukuhara H; Todo T Curr Cancer Drug Targets; 2007 Mar; 7(2):149-55. PubMed ID: 17346106 [TBL] [Abstract][Full Text] [Related]
27. Replicative oncolytic herpes simplex viruses in combination cancer therapies. Post DE; Fulci G; Chiocca EA; Van Meir EG Curr Gene Ther; 2004 Mar; 4(1):41-51. PubMed ID: 15032613 [TBL] [Abstract][Full Text] [Related]
28. Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells. Petrovic B; Leoni V; Gatta V; Zaghini A; Vannini A; Campadelli-Fiume G J Virol; 2018 Mar; 92(6):. PubMed ID: 29263257 [TBL] [Abstract][Full Text] [Related]
29. Combination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancer. Zager JS; Delman KA; Malhotra S; Ebright MI; Bennett JJ; Kates T; Halterman M; Federoff H; Fong Y Mol Med; 2001 Aug; 7(8):561-8. PubMed ID: 11591892 [TBL] [Abstract][Full Text] [Related]
35. Herpes Simplex Virus 1 Infection Promotes the Growth of a Subpopulation of Tumor Cells in Three-Dimensional Uveal Melanoma Cultures. Valyi-Nagy T; Fredericks B; Ravindra A; Hopkins J; Shukla D; Valyi-Nagy K J Virol; 2018 Oct; 92(19):. PubMed ID: 30045986 [TBL] [Abstract][Full Text] [Related]
36. Ultrasound as a method to enhance antitumor ability of oncolytic herpes simplex virus for head and neck cancer. Okunaga S; Takasu A; Meshii N; Imai T; Hamada M; Iwai S; Yura Y Cancer Gene Ther; 2015 Apr; 22(3):163-8. PubMed ID: 25656776 [TBL] [Abstract][Full Text] [Related]
37. Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Fu X; Tao L; Wang PY; Cripe TP; Zhang X Oncotarget; 2018 Apr; 9(30):21348-21358. PubMed ID: 29765544 [TBL] [Abstract][Full Text] [Related]
38. Feasibility of herpes simplex virus type 1 mutants labeled with radionuclides for tumor treatment. Mi YX; Long YH; Li YC World J Gastroenterol; 2008 Mar; 14(9):1321-5. PubMed ID: 18322942 [TBL] [Abstract][Full Text] [Related]
39. Tumour-specific triple-regulated oncolytic herpes virus to target glioma. Delwar ZM; Liu G; Kuo Y; Lee C; Bu L; Rennie PS; Jia WW Oncotarget; 2016 May; 7(19):28658-69. PubMed ID: 27070093 [TBL] [Abstract][Full Text] [Related]
40. Herpes simplex virus oncolytic vaccine therapy in melanoma. Sivendran S; Pan M; Kaufman HL; Saenger Y Expert Opin Biol Ther; 2010 Jul; 10(7):1145-53. PubMed ID: 20515292 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]